CD274 and colorectal carcinoma: Notably, 5% of patients with stage IV CRC presenting a dMMR or MSI‐H tumor‐mediating high mutation burdens and unique immunogenic profiles are now eligible for treatment with anti‐PD‐1 or anti‐PD‐L1 antibodies, the first targeted immunotherapies approved for the treatment of CRC [6].